MBS Doubles Capacity for In Vitro Antibody Production

September 4th, 2014

In response to customer demand, MBS has significantly expanded roller bottle production space to continue efficient order processing.

Trust MBS to answer the critical questions for successful In Vitro antibody production:

  • Do you have an appropriate sized cell bank?
  • Are the media conditions optimized?  Is serum free media required?
  • Are endotoxin and contaminating proteins (e.g. bovine IgG) important to avoid for your end use?
  • Does QA validation require 3 lots?
  • What are the final parameters required for final concentration, preservatives, and aliquot size ?
  • What is your long term supply forecast?

Contact us at 207-797-5454 or sales@mainebiotechnology to book your ascites or in vitro antibody production today.


Read More.



Recombinant Protein Expression Now Available at Maine Biotechnology Services

June 18th, 2014

Portland Maine – Bacterial recombinant protein expression is now available as a service at Maine Biotechnology Services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production.

Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification services to compliment our complete antibody service offering, adding value and efficiency to custom antibody development with MBS.

A typical recombinant antigen project at MBS will begin with a careful analysis of the protein sequence and characteristics to assess its suitability for bacterial expression. MBS will use this early analysis to anticipate potential risks and guide an expression strategy. After an expression construct has been obtained and the sequence verified, protein production will be evaluated in a small scale trial. Because bacterial recombinant protein expression always possesses the risk of low expression levels or insoluble expression, it is important to have a thorough evaluation process that saves time while also increasing the likelihood of positive outcomes. MBS developed a parallel small scale evaluation method that assesses multiple expression conditions to provide meaningful information regarding expression, isolation, and purification. The result is an efficient early evaluation that produces predictable large scale outcomes thereby supplying ample antigen for antibody development as quickly as possible.

As a company with rich experience in developing custom antibodies to difficult targets, Maine Biotechnology Services brings the specialized perspective of antibody development professionals to recombinant protein development services. When MBS develops recombinant antigen for a hybridoma development, the end use application of the antibodies is considered during every phase of antigen production. When protein production is complete, MBS provides a seamless transition to immunizations, shortening the overall timeline to obtain antibodies that meet end use requirements.

About Maine Biotechnology Services: Maine Biotechnology Services is a premier provider of antibody services, with a rich core competency in custom hybridoma development, production and characterization. A wide variety of tools and processes have been developed by MBS to refine clone selection early in a project, and to support customers all the way through functional assay preparation. It is the goal of MBS R&D to continuously add quality, synergistic services that create the most convenient and comprehensive antibody development process possible for our customers.

GST Monoclonal Antibody – Glutathione S-transferase

June 16th, 2014

MAB241P, a monoclonal antibody specific for GST-tag, is part of a growing list of MBS products aimed at assisting our customers in the detection of recombinant proteins.  MBS R&D developed the murine antibody using recombinant GST as an immunogen.  MAB241P was shown to recognize N or C terminal GST fusion proteins as well as recombinant GST protein in Western Blot.  The internal development and production of MAB241P allows MBS to maintain the highest quality standards and the ability to offer the lowest possible price.

JO GST Blot with caption




• Applications: Validated in western blot

• Reactivity: Recognizes free GST, C terminal and N-terminal GST fusion proteins

• Value: 100ug sample sizes available with promotional pricing of $75.00 for a limited time.












Other tag antibodies available from MBS include antibodies to His-tag and Maltose Binding Protein.

Contact us for bulk pricing at

Food poisoning? It was likely a restaurant worker, says CDC – The Chart – Blogs

June 4th, 2014

Food poisoning? It was likely a restaurant worker, says CDC
Approximately 20 million people fall ill every year due to norovirus, according to a new report from the Centers for Disease Control and Prevention, which says the food service industry could do much to decrease that number.

Restaurants and catering services are the most common sources for norovirus outbreaks from contaminated food, according to the report. “Infected food workers are frequently the source of these outbreaks, often by touching ready-to-eat foods served in restaurants with their bare hands,” CDC experts wrote.

Norovirus is the most common cause of acute gastroenteritis – often called a stomach bug – in the United States, according to the CDC. Symptoms generally include stomach pain, nausea and diarrhea.

Norovirus particles spread whenever an infected person vomits or defecates. Because swallowing just 18 norovirus particles can sicken a new host, the virus spreads easily, especially when the infected patient is preparing food for a lot of people.

Norovirus is also hardy: It can live for up to two weeks on countertops, survive freezing temperatures, and is resistant to many disinfectants and hand sanitizer.

The way to prevent infections via restaurants and catering businesses, says the CDC, is for workers to thoroughly wash their hands with soap and water, and to stay home for at least 48 hours after symptoms stop.

Unfortunately, that does not seem to be happening.

One in five food service workers say they have worked while sick with vomiting and diarrhea due to “fear of job loss” and “not wanting to leave co-workers short-staffed,” according to the report.

The CDC recommends that the food industry address these problems both with new policies and by better adhering to food safety laws and regulations that are already in place.

“Businesses can consider using measures that would encourage sick workers to stay home, such as paid sick leave and a staffing plan that includes on-call workers,” said the CDC’s Aron Hall.

While infected workers cause 70% of norovirus outbreaks from contaminated food, according to the report, the vast majority of norovirus outbreaks are non-foodborne, and occur in long-term care facilities such as hospices, nursing and assisted living homes.

Learn more about the MBS panel of Norovirus antibodies that including Sydney strain. 

via Food poisoning? It was likely a restaurant worker, says CDC – The Chart – Blogs.

E. coli Recombinant Antigen Expression Now Available

June 2nd, 2014

Antigen Sequence to Monoclonal Antibody

For 25 years, Maine Biotechnology Services has been a leading provider of quality antibody reagents in both research and diagnostic fields.  MBS has long been able to leverage internal custom antibody service expertise to design, develop, and support the highest quality antibodies at affordable prices.  Three years ago, MBS built a new lab and dedicated research and development scientists to the endeavor of adding recombinant protein production capabilities to the MBS skill set.  After a year of R&D, MBS began to regularly use internal recombinant antigen production to support antibody product development.  Many of the most successful commercial antibody products in our reagent catalog, originated in the MBS recombinant lab. MBS is now proud to offer recombinant antigen production to our antibody development service customers.  The unique value Maine Biotechnology Services brings to recombinant protein production is the foresight to anticipate how the attributes of the recombinant protein will affect the goals of a hybridoma development in order to maximize the potential for total project success.

MBS E. coli Recombinant Protein Expression

  • An ample volume of E. coli expressed recombinant protein to support monoclonal antibody development
  • Project strategy and protein evaluation performed with a process designed to maximize expression levels and solubility. Fast and efficient execution while providing customers with real time project updates in order to make timely decisions
  • Hybridoma development strategy is designed to accommodate each recombinant protein’s characteristics.

Rec Flow chart fixed 061014


For more information on E. coli recombinant protein expression click here.

Contact us for a quote or to discuss project specifics.





MBS at BIO and AACC 2014

May 13th, 2014

MBS will be attending BIO International Convention in San Diego, California June 23rd-26th.  We will also be exhibiting at AACC booth #3748 in Chicago, Illinois July 29th-31st.  Meet with MBS Sales representatives to learn more about our growing service and product catalogs.  2014 is an exciting year at MBS as we roll out the long awaited additions of recombinant antigen production services as well as early assay development work to our established antibody development and production core services.  MBS is now proud to deliver recombinant antigens developed with hybridoma development and customer end uses in mind, fully characterized purified antibodies, and early functional matched pair assays.  Also from MBS R&D, the antibody reagent catalog continues to grow to now include antibodies to Norovirus, Rotavirus, Adenovirus, HIS-tag, Polyethylene glycol (PEG), Rift Valley Fever Virus, GST tag, Campylobacter jejuni, and many more.  

Contact us to set up a meeting at BIO International or AACC Conferences.  

AACC Logo banner

Chikungunya now an epidemic in the Caribbean

May 2nd, 2014

Chikungunya now an epidemic in the Caribbean                                       

Thursday, May 01, 2014 | 2:07 PM     

ORANJESTAD, Aruba (CMC) – The head of the Caribbean Public Health Authority (CARPHA), Dr James Hospedales, has declared the Chikungunya virus has reached epidemic proportions in the Caribbean.
“By definition this is an epidemic since it represents an unusual number of cases of this problem where we would never have it before,” Dr Hospedales told the Caribbean Media Corporation (CMC).

The mosquito-borne illness was first detected in the Caribbean in December 2013, in St Martin, and last week Antigua and St Vincent and the Grenadines became the latest countries to declare an outbreak.

According to Dr Hospedales, as of April 28, there were 4,108 probable cases in 14 countries across the region.

He also stated that Caribbean countries have been putting measures in place to address the spread of the virus.

“PAHO (the Pan American Health Organisation) since 2012 had done a preparatory briefing, in July of last year we convened a Caribbean-wide virtual meeting of the chief officers in the countries in the labs, to highlight this emerging threat and to adjust our surveillance protocols and laboratory testing to have early detection.

“In December, once it came into the region we established an incident management team, and that has regular contact with the countries, with PAHO, with the French and so on,” Hospedales said.

Chikungunya is spread by the Aedes Egypti mosquito, which also spreads dengue fever.

Hospedales noted there are steps that can be taken to contain the disease.

“Our main recommendations are to continue to educate members of the public on the current situation, and get accurate information to avoid confusion.

“It is very important to inspect homes and communities to eliminate potential vector breeding sites for the Aedes Egypti mosquito,” he said.

He also advised that people who are sick with fever and suspect they may be suffering from dengue or Chikungunya, should use an insect repellant and sleep under a mosquito net.

“This is not a severe disease, in that people don’t die from it, whereas dengue can kill you, but Chikungunya has more long term a significant per cent of people will have joint pains one year, two years afterwards,” Hospedales said.

To date the Chikungunya virus has been confirmed in Anguilla, Aruba, Virgin Islands, Dominica, Dominican Republic, French Guiana, Guadeloupe, Martinique, St Barthelemy, St Kitts and Nevis, St Lucia, St Vincent and the Grenadines, St Maarten (Dutch) and St Martin (French)

Contact us to reserve samples of anti-Chikungunya virus antibodies currently in development at MBS 

via Chikungunya now an epidemic in the Caribbean – Latest News –

MBS-USDA Rift Valley Fever Virus Partnership

April 17th, 2014

Two monoclonal antibodies to the nucleocapsid protein of Rift Valley Fever Virus (RVFV), MAB239P and MAB240P, are now available for sampling from MBS R&D. The clones are a result of a partnership between MBS and the USDA-Agricultural Research Service  (USDA-ARS) to develop detection reagents for RVFV assays.

For this project, mice were immunized with RVFV lysates and screened for recognition of recombinant nucleocapsid protein (rNP). A sandwich ELISA against rNP demonstrated a sensitivity level of at least 6 ng/ml.


 The clones were then screened by USDA-ARS by indirect ELISA against native virus to confirm specificity. 


In the final phase of validation for the antibodies, Dr. Scott McVey, supervisor of the USDA Arthropod Borne Animal Disease Research Unit (ABADRU), intends to deliver them to the USDA-ARS partnered laboratories in South Africa and other endemic African nations for assay development with clinical samples.  Future goals of the MBS-USDA-ARS Rift Valley Fever program include the development of antibodies to NSs proteins to support vaccine programs.

Link to the USDA Project Description 


MBS Sales Director Interviewed in Drug Development and Delivery: Early-Stage Partnerships Are On The Rise

April 16th, 2014


MBS provides monoclonal and polyclonal antibody services, from design and development to production, characterization, and assay development. MBS works with both pharmaceutical and diagnostic companies to develop antibodies against their targets of interest, which may include small molecules, recombinant antigens, peptides, and anti-idiotypes. Tools such as MultiPure technology and Octet Red kinetic analysis are used to allow customers the opportunity to refine their clone selection earlier in the process. The antibodies developed by MBS are used by customers to support therapeutic product release and clinical trials, as well as within their 510K-approved diagnostic kits. 

As Carrie Rice, Sales Director at MBS, explains, “Our pharmaceutical customers increasingly have a need to develop anti-idiotypic antibodies for antibody neutralization assays. Anti-Id antibody candidates are screened for the ability to neutralize or block specific ligand binding of a therapeutic antibody. Monitoring therapeutic antibodies in clinical samples requires the ability to differentiate between administered antibody and naturally occurring endogenous antibodies. This has become increasingly difficult as antibody biotherapeutics more closely resemble circulating human immunoglobulins. Anti-idiotypic antibodies specific for the unique variable region of the therapeutic antibody are ideal for this purpose.”

The most common end applications for anti-id antibodies developed at MBS are in the space of preclinical research for therapeutic antibodies. They can be used as reagents in pharmacokinetic studies, immune response immunogenicity assays, in ligand binding or neutralizing studies, or in antibody blocking assays.

In the past year, MBS has built on 25 years’ experience in hybridoma development to offer anti-idiotypic antibody development. “For some of our pharmaceutical customers, developing the research use assays required for drug monitoring is a challenge or distraction that they do not want to divert their internal R&D resources to. In order to respond to that customer need, MBS has added assay development services to our offerings so that we may assist the customer one step further in the process,” explains Ms. Rice. “We are now regularly evaluating antibody performance in sandwich ELISAs and bridging assays for customers. Pharma customers can now take clones with known performance and supporting data straight to their CRO for clinical assay development.”

Ms. Rice describes one client’s antibody development program. “One of our customers was faced with a challenge that we hear from so many: Get a companion assay up and running as soon as possible so that we can get our clinical trials going. As MBS had been part of the original antibody development program, we went back to our inventory and revived antibodies that had already been developed. We optimized assays that had already been used in the development program and made them robust and repeatable enough to be transferred to a clinical lab for assay development work. Had our customer gone back to square one, developing an assay could have added 9-12 months and tens of thousands of dollars to their program.”

MBS finds itself in an evolving market and that could affect the service pharma customers can expect from providers. “The industry is experiencing a wave of acquisitions and outsourced manufacturing by antibody service providers to overseas providers. Sometimes that outsourcing is obvious and sometimes it is not made clear to the customer. Often, the pricing for projects undercuts the service providers that have longevity here in the United States. The risk, in our view, is that as the industry trends toward needing more and complex hybridoma developments in the anti-idiotypic space,” she says. “Base model providers with canned approaches will likely not be able to meet the growing challenges that anti-idiotypic developments present.”

via SPECIAL FEATURE – Outsourcing Formulation Development & Manufacturing: Early-Stage Partnerships Are On The Rise | Articles | Back Issues | Drug Development & Delivery.

Subscribe to Drug Development and Delivery 

Anti-HIS tag Antibody from MBS Incorporated into ForteBio Dip and Read Anti-HIS (HIS2) Biosensors

March 13th, 2014

Portland Maine -  MBS MAB230P, monoclonal antibody to the polyhistidine (HIS) tag has been incorporated into the second generation Forte Bio Anti-HIS biosensors for rapid quantitative measurement of HIS tagged proteins.  MAB230P was selected by ForteBio after demonstrating high specificity and excellent sensitivity, detecting HIS tagged proteins in nanogram quantities.  The antibody is broadly reactive, recognizing HIS tags of 4X or greater, engineered at either the N- or C-terminus of the protein. The internal development and production of MAB230P allows MBS to maintain the highest quality standards and the ability to offer the lowest price in the marketplace. 

The MAB230P anti-(HIS) tag antibody, is part of a growing list of MBS products aimed at assisting our customers in the detection of recombinant proteins.  Quality, affordable antibodies to Maltose Binding Protein (MBP) and Glutathione S-transferase (GST) tags are also available at MBS.  A project to develop new antibodies to the DYKDDDK peptide epitope tag is ongoing. HIS-tag is the most popular recombinant protein tag and MAB230P is widely sampled and used by customers with need for a high affinity, highly specific HIS-tag antibody. 

About Maine Biotechnology Services:  Maine Biotechnology Services is a premier provider of antibody services, from design and development to production and characterization. A wide variety of tools are utilized by MBS to refine clone selection early in a project, and to support prototype assay validation.  MBS is able to apply 25 years experience in custom hybridoma projects to the development of antibody product reagents.  It is the goal of MBS to maintain a small, internally developed, well supported catalog of antibodies that offer the highest quality performance at the lowest pricing, direct from the manufacturer.

About ForteBio Dip and Read Anti-HIS (HIS2) Biosensors – Pre-immobilized with the next generation high-affinity, high-specificity Anti-HIS antibody from Maine Biotechnology Services (MBS), the Anti-HIS (HIS2) Biosensor directly captures and detects HIS-tagged proteins for quick and easy quantitative measurement.  Key features include the rapid detection of HIS-tagged proteins, high-specificity capture of HIS-tagged proteins for easy quantitation and rapid analysis of crude or purified samples.   Octet® biosensors and assay kits are configured in a standard 96-well format, for your convenience. They are compatible with all Octet instruments (whether using 96- or 384-well plates)

 MAB230P  100ug $200.00   1mg $425.00

The information provided on this website is for informational and educational purposes only. This information should not be construed as rendering legal advice or offering an answer to a specific legal problem.